{% extends "base/base.html.twig" %}

{# Beginning of Page Header #}
{% block pageTitle %}
Oral Chemotherapy - University of Alberta | Improving drug dosing and use
{% endblock pageTitle %}

{% block pageStylesheets %}
<link href="/css/live_global.css" rel="stylesheet">
{% endblock pageStylesheets %}

{# Beginning of Page Content #}
{% block aboutActive %}
class="active"
{% endblock aboutActive %}

{% block content %}
<!-- Body Content -->
<h1 class="page-header">About</h1>
<div>
    <h3>Disclaimer</h3>
    <p>&nbsp;&nbsp;&nbsp;&nbsp;The contents of the AntiC App are intended to assist non-oncology pharmacists &
        allied health-care professionals to identify problems associated with oral chemotherapy. While there is public access,
        it must be understood that the information is not intended as medical advice, which should be provided by a clinician,
        with the health information, necessary to identify the individualâ€™s requirements. The information provided on the AntiC
        App is intended primarily for use in Canada, and may not apply to other jurisdictions. The authors disclaim any liability,
        loss, injury or damage incurred as a consequence, directly or indirectly, by the use and or application of any of the
        contents of the AntiC App.</p>
</div>
<div>
    <h3>Glossary</h3>
    <table class="table table-striped table-bordered">
        <tbody>
            <tr>
                <td><strong>Abortifacient</strong></td>
                <td>Any agent which may produce abortion.</td>
            </tr>

            <tr>
                <td><strong>Cancer</strong></td>
                <td>A broad group of diseases involving unregulated cell growth. In cancer, cells divide and grow uncontrollably, forming malignant tumours, and invading nearby parts of the body.</td>
            </tr>

            <tr>
                <td><strong>Carcinogenic</strong></td>
                <td>Having the potential to cause cancer.</td>
            </tr>

            <tr>
                <td><strong>Chemotherapeautics</strong></td>
                <td>The treatment of cancer using specific chemical agents or drugs that are selectively destructive to malignant cells and tissues.</td>
            </tr>

            <tr>
                <td><strong>Chemotherapy</strong></td>
                <td>The treatment of cancer with one or more cytotoxic anti-neoplastic drugs as part of a standardized regimen.</td>
            </tr>

            <tr>
                <td><strong>Clastogenic</strong></td>
                <td>Having the potential to cause disruption or breakage of chromosomes.</td>
            </tr>

            <tr>
                <td><strong>Cytotoxic</strong></td>
                <td>Detrimental or destructive to cells.</td>
            </tr>

            <tr>
                <td><strong>Dose</strong></td>
                <td>A specified quantity of a therapeutic agent, such as a drug or medicine, prescribed to be taken at one time or at stated intervals.</td>
            </tr>

            <tr>
                <td><strong>Embryo-lethal</strong></td>
                <td>Having the potential to cause death of the embryo.</td>
            </tr>

            <tr>
                <td><strong>Embryotoxic</strong></td>
                <td>Causing injury to the embryo, which may result in death or abnormal development of a part due to entering the placental circulation.</td>
            </tr>

            <tr>
                <td><strong>Fetotoxic</strong></td>
                <td>A substance poisonous to the fetus.</td>
            </tr>

            <tr>
                <td><strong>Half-life</strong></td>
                <td>The time required for half the quantity of a drug or other substance deposited in a living organism to be metabolised or eliminated by normal biological processes.</td>
            </tr>

            <tr>
                <td><strong>Inducer</strong></td>
                <td>A substance that induces, especially a substance that is capable of activating transcription from specific genes within a cell.</td>
            </tr>

            <tr>
                <td><strong>Infarction</strong></td>
                <td>Tissue death (necrosis) caused by a local lack of oxygen, due to an obstruction of the tissue's blood supply.</td>
            </tr>

            <tr>
                <td><strong>Inhibitor</strong></td>
                <td>A substance that reduces or suppresses the activity of another substance (such as an enzyme).</td>
            </tr>

            <tr>
                <td><strong>Leukemia</strong></td>
                <td>Cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts".</td>
            </tr>

            <tr>
                <td><strong>Malignant</strong></td>
                <td>Very virulent or infectious.</td>

            </tr>
            <tr>
                <td><strong>Medical protocol</strong></td>
                <td>Medical guidelines for a medical treatment. It usually includes a treatment plan, summarized consensus statements and addresses practical issues.</td>
            </tr>

            <tr>
                <td><strong>Metastasis</strong></td>
                <td>The spread of a cancer from one organ or part to another non-adjacent organ or part.</td>
            </tr>

            <tr>
                <td><strong>Mutagenic</strong></td>
                <td>A substance which may cause mutation.</td>
            </tr>

            <tr>
                <td><strong>Oncology</strong></td>
                <td>The study and treatment of tumours.</td>
            </tr>

            <tr>
                <td><strong>Radiation therapy</strong></td>
                <td>The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.</td>
            </tr>

            <tr>
                <td><strong>Risk stratification</strong></td>
                <td>A statistical process to determine detectable characteristics associated with an increased chance of experiencing unwanted outcomes.</td>
            </tr>

            <tr>
                <td><strong>Substrate</strong></td>
                <td>The reactant which is consumed during a catalytic or enzymatic reaction.</td>
            </tr>

            <tr>
                <td><strong>Teratogenic</strong></td>
                <td>Having the potential to cause congenital abnormalities or birth tdects.</td>
            </tr>

            <tr>
                <td><strong>Toxicity</strong></td>
                <td>The degree to which a substance can damage an organism.</td>
            </tr>
        </tbody>
    </table>
</div>
<div>
    <h3>The Team</h3>
    <b>Project Conception and Medical Consultants:</b>
    <ul>
        <li><b>Tibor van Rooij</b>, Ph.D. Candidate, Pharmacy and Pharmaceutical Sciences, University of Alberta</li>
        <li><b>Serena Rix</b>, Pharm.D., Grey Nuns Community Hospital, Edmonton, Alberta</li>
        <li><b>Sharon Marsh</b>, Ph.D., Assistant Professor, Pharmacy and Pharmaceutical Sciences, University of Alberta</li>
    </ul>
    <b>Development Team:</b>
    <ul>
        <li><b>James Cadek</b> - University of Alberta</li>
        <li><b>Zachary Lubinski</b> - University of Alberta</li>
        <li><b>James Moore</b> - University of Alberta</li>
        <li><b>Kyle Ross</b> - University of Alberta</li>
        <li><b>Tanvir Sajed</b> - University of Alberta</li>
        <li><b>Jeremy Smereka</b> - University of Alberta</li>
        <li><b>Scott Vig</b> - University of Alberta</li>
    </ul>
</div>
<div>
    <h3>Resources</h3>
    <ul>
        <li><a href="http://oralchemotherapy.ca/wordpress/">Oral Chemotherapy Website</a></li>
        <li><a href="http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/default.htm">BC Cancer Agency Website</a></li>
        <li><a href="https://www.cancercare.on.ca/cms/One.aspx">Cancer Care Ontario Website</a></li>	
        <li><a href="http://www.acrin.org/Portals/0/Administration/Regulatory/CTCAE_4.02_2009-09-15_QuickReference_5x7.pdf">NCI Common Toxicity Criteria (Version 4, 2009)</a></li>
        <li><a href="http://www.sads.org.uk/drugs_to_avoid.htm">QTc Interval Prolonging Agents</a></li>
        <li><a href="http://www.mhc.com//Cytochromes//PGP//PgpTable.HTML">P-glycoprotein Drug Interactions</a></li>
    </ul>
</div>
<div>
    <h3>Version</h3>
    <p>Version 1.0</p>
</div>
{% endblock content %}
